Compass therapeutics announces presentation on ctx-8371, a bispecific antibody targeting pd-1 and pd-l1, at the 2022 aacr annual meeting in new orleans

Boston, march 30, 2022 (globe newswire) -- compass therapeutics inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced today that it will present preclinical data on ctx-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets pd-1 and pd-l1 at the upcoming american association for cancer research (aacr) annual meeting, which is being held april 8-13, 2022, at the ernest n. morial convention center in new orleans, louisiana.
CMPX Ratings Summary
CMPX Quant Ranking